Physician profile
Corazon Veloso
NPI 1861443855
$645.44
in general payments reported to CMS, 2019-2025
10 companies · $272 in 2025
The $272 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.50 · 2023: $31.77 · 2024: $329 · 2025: $272.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $632.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $631.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $249.48 | 2024 | Arexvy, Shingrix |
| Exact Sciences Corporation | $214.15 | 2023-2025 | Cologuard Collection Kit |
| Phadia US INC. | $46.16 | 2024 | Immunocap |
| Pfizer INC. | $34.94 | 2025 | |
| Novo Nordisk INC | $19.79 | 2025 | |
| Dynavax Technologies Corporation | $17.11 | 2024 | Heplisav-B |
| Astrazeneca Pharmaceuticals LP | $17.06 | 2025 | Fasenra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.00 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $16.25 | 2025 | Zoryve |
| Genentech USA, INC. | $13.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Corazon Veloso listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.